Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan

doi:10.4254/wjh.v2.i10.374

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 10

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5736)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

434

HTML

4982

Figures (1-1)

138

Tables (1-5)

182

Sum=5736

Oct 27, 2010 (publication date) through Jul 25, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Oct 27, 2010; 2(10): 374-383
Published online Oct 27, 2010. doi: 10.4254/wjh.v2.i10.374

Table 4 Panel markers for fibrosis in nonalcoholic fatty liver disease

Index	Author (Nation)	Paper	Parameter	Patient selection	N	Stage	AUROC
	Angulo P (USA)	Hepatology 1999	Obesity¹, age, AST/ALT ratio, DM	NASH	144	F0-2 vs F3-4
BAAT	Ratziu V (France)	Gastroenterology 2000	BMI, age, ALT, TG	Patients with BMI>25, raised transaminse	93	F0-1 vs F2-4	0.840
FibroTest (FT)	Ratziu V (France)	BMC Gastroenterol 2006	Age, sex, α2-macroglobulin, , apolipoprotein A1, haptoglobin, T-Bil, γGT	Biopsy proven NAFLD	267	F0-2 vs F3-4	0.840
N score	Miyaaki H (Japan)	Liver Int 2008	Female, age, DM, HT	Biopsy proven NAFLD	182	F0-2 vs F3-4	0.780
NAFLD fibrosis score	Angulo P (USA, UK, Australia, Italy)	Hepatology 2007	Age, BMI, AST/ALT ratio, IFG/DM, platelet count, albumin	Biopsy proven NAFLD	480²	F0-2 vs F3-4	0.880²
NAFLD fibrosis score	Angulo P (USA, UK, Australia, Italy)	Hepatology 2007	Age, BMI, AST/ALT ratio, IFG/DM, platelet count, albumin	Biopsy proven NAFLD	253³	F0-2 vs F3-4	0.820³
ELF panel	Guha IN (UK)	Hepatology 2008	TIMP1, HA, P3NP	Biopsy proven NAFLD	192	F0 vs F1-4	0.820
						F0-1 vs F2-4	0.900
						F0-2 vs F3-4	0.930
BARD score	Harrison SA (USA)	Gut 2008	BMI, AST/ALT, DM	Biopsy proven NAFLD	827	F0-2 vs F3-4	0.810²
BARD score	Harrison SA (USA)	Gut 2008	BMI, AST/ALT, DM	Biopsy proven NAFLD	827	F0-2 vs F3-4	0.780³
FIB4 index	Shah (USA)	Clin Gastroenterol Hepatol 2009	Age, AST, ALT, PLT	Biopsy proven NAFLD	541	F0-2 vs F3-4	0.802
FibroMeter	Calès (France)	J Hepatol 2009	Glucose , AST, ferritin, PLT, ALT, BW, age	Biopsy proven NAFLD	235	F0-1 vs F2-4	0.936²
FibroMeter	Calès (France)	J Hepatol 2009	Glucose , AST, ferritin, PLT, ALT, BW, age	Biopsy proven NAFLD	235	F0-1 vs F2-4	0.952³
PAF	Hossain (USA)	Clin Gastroenterol Hepatol 2009	Male , Caucasian, DM, ALT, AST	Biopsy proven NAFLD	432	F0-1 vs F2-4	0.742

¹BMI > 31.1 (male), 32.2 (female);

²Estimation group;

³Validation group; TG: triglyceride; IFG: impaired fasting glycemia; TIMP1: tissue inhibitor of metalloproteinases; HA: hyaluronic acid; P3NP: type III procollagen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BMI: body mass index; PLT: platelets; γGT: γ-glutamyl transferase; T-Bil: total bilirubin; DM: diabetes mellitus; BW: body weight; AUROC: area under the receiver operating characteristic curve; NAFLD: nonalcoholic fatty liver disease; NASH: nonalcoholic steatohepatitis.

Citation: Sumida Y, Eguchi Y, Ono M. Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol 2010; 2(10): 374-383
URL: https://www.wjgnet.com/1948-5182/full/v2/i10/374.htm
DOI: https://dx.doi.org/10.4254/wjh.v2.i10.374